016580.KS
Whan In Pharm Co.,Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 10,480.00
+3.35%Year over year
Reported trailing growth
- Revenue
- +9.0%
- EBITDA
- -18.0%
- EBIT
- +111.2%
- EPS
- +30.2%
- Free cash flow
- +217.3%
- Operating cash flow
- -12.2%
Forward estimates
Based on analyst estimates
- Revenue
- -74.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.7%
- EBITDA
- -11.7%
- EBIT
- -24.1%
- Net income
- -17.2%
- EPS
- -18.2%
- Free cash flow
- +171.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026